Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 50,191 | 0 | 0 | 0 | 12,877 |
| Marketable Securities | 45,927 | 0 | 0 | 0 | 0 |
| Other current assets | 3,441 | 0 | 0 | 0 | 762 |
| TOTAL | $104,951 | $0 | $0 | $0 | $13,639 |
| Non-Current Assets | |||||
| PPE Net | 474 | N/A | N/A | N/A | 152 |
| Other Non-Current Assets | 189 | 0 | 0 | 0 | 314 |
| TOTAL | $663 | $N/A | $N/A | $N/A | $466 |
| Total Assets | $105,614 | $0 | $0 | $0 | $14,104 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,372 | 0 | 0 | 0 | 3,613 |
| Accrued Expenses | 13,024 | 0 | 0 | 0 | 3,713 |
| TOTAL | $17,396 | $0 | $0 | $0 | $7,326 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 0 | 0 | 0 | 1,425 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2 |
| TOTAL | $35 | $N/A | $N/A | $N/A | $1,441 |
| Total Liabilities | $17,431 | $0 | $0 | $0 | $8,767 |
| Shareholders' Equity | |||||
| Common Shares | 1 | 0 | 0 | 0 | 1 |
| Retained earnings | -155,845 | 0 | 0 | 0 | -67,914 |
| Other shareholders' equity | 239,360 | 0 | 0 | 0 | 72,062 |
| TOTAL | $88,183 | $0 | $0 | $0 | $5,337 |
| Total Liabilities And Equity | $105,614 | $0 | $0 | $0 | $14,104 |